Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy.      (abst – 1975)










Delta-9-Tetrahydrocannibinol as an Antiemetic in Cancer Patients Receiving High-Dose Methotrexate   (full – 1979)                   


Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo.                                                                       (abst – 1979)


Delta-9-tetrahydrocannabinol (THC) as an antiemetic in patients treated with cancer chemotherapy; a double-blind cross-over trial against placebo                                                                 (abst – 1979)


Amelioration of cancer chemotherapy-induced nausea and vomiting by delta-9- tetrahydrocannabinol.    (abst – 1979)


Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy.                                                 (abst – 1979)


Antiemetic effect of tetrahydrocannabinol. Compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis.                                             (abst – 1980)


The antiemetic activity of tetrahydrocanabinol versus metoclopramide and thiethylperazine in patients undergoing cancer chemotherapy.                                                                              (abst – 1980)


Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine.                         (abst – 1980)


Double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on chemotherapy-induced emesis.                                                    (abst – 1980)


Physiologic observations in a controlled clinical trial of the antiemetic effectiveness of 5, 10, and 15 mg of delta 9-tetrahydrocannabinol in cancer chemotherapy. Ophthalmologic implications.       (abst – 1981)


Clinical experience with levonantradol hydrochloride in the prevention of cancer chemotherapy-induced nausea and vomiting.                                                                      (abst – 1981)


Dose vs response of tetrahydroannabinol (THC) vs prochlorperazine as chemotherapy antiemetics.          (abst – 1981)










Comparative trial of the antiemetic effects of THC and haloperidol               (abst – 1981)


Levonantradol, a new antiemetic with a high rate of side-effects for the prevention of nausea and vomiting in patients receiving cancer chemotherapy.                                                       (abst – 1982)


Cannabis and cancer chemotherapy: a comparison of oral delta-9-THC and prochlorperazine.       (abst – 1982)                                


A double-blind, controlled trial of nabilone vs. prochlorperazine for refractory emesis induced by cancer chemotherapy.                                             (abst – 1982)


A multi-institutional Phase III study of nabilone vs. placebo in chemotherapy-induced nausea and vomiting.                                                  (abst – 1982)


Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy.       (full – 1983)


Levonantradol: a synthetic cannabinoid in the treatment of severe chemotherapy-induced nausea and vomiting resistant to conventional anti-emetic therapy.                                              (abst – 1983)


Antiemetic efficacy of levonantradol compared to delta-9-tetrahydrocannabinol for chemotherapy-induced nausea and vomiting.                                                               (abst – 1985)


THC or Compazine for the cancer chemotherapy patient–the UCLA study. Part II: Patient drug preference.                                                      (abst – 1985)


A cross-over comparison of nabilone and prochlorperazine for emesis induced by cancer chemotherapy. (abst – 1985)


Nabilone: an alternative antiemetic for cancer chemotherapy.              (full – 1986)


Crossover comparison of the antiemetic efficacy of nabilone and alizapride in patients with nonseminomatous testicular cancer receiving cisplatin therapy                                                       (abst – 1986)


Prospective randomized double-blind trial of nabilone versus domperidone in the treatment of cytotoxic-induced emesis.                                                                 (abst – 1986)







Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: a double-blind, crossover trial.                                                       (abst – 1987)


Efficacy of tetrahydrocannabinol in patients refractory to standard anti-emetic therapy (abst – 1988)                           


A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues.                                                                                           (abst – 1988)


Marijuana as antiemetic medicine : A Survey of Oncologists’ Experiences and Attitudes (full – 1991)                          


Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy- induced nausea and vomiting.                                              (abst – 1991)


An efficient new cannabinoid antiemetic in pediatric oncology               (full – 1995)


Therapeutic Aspects of Cannabis and Cannabinoids             (full – 2001)


Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review            (full – 2001)


The cannabinoids: an overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection. (abst – 2001)                            


Different views on the association between cannabinoids and cancer             (abst – 2006)  tplus


Dronabinol for supportive therapy in patients with malignant melanoma and liver metastases        (abst – 2006)                      


2nd synthetic marijuana drug OK’d for chemo effects                (news – 2006)


Cesamet, THC and chemotherapy              (news – 2006)









Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats.                                       (full – 2007)


Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting: beyond prevention of acute emesis.                                                       (abst – 2007)


Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting.                                          (abst – 2007) med_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum


Pot Compound May Offer “Non-Toxic” Alternative To Chemotherapy               (news – 2007)


Pharmacological Inhibition of CB1 Cannabinoid Receptor Protects Against Doxorubicin- Induced Cardiotoxicity                                                    (full – 2008)


Oral nabilone capsules in the treatment of chemotherapy-induced nausea and vomiting and pain. (abst – 2008)                 


Pharmacological synergism between cannabinoids and paclitaxel in gastric cancer cell lines.         (abst – 2009)          


Efficacy of Crude Marijuana and Synthetic Delta-9-Tetrahydrocannabinol as Treatment for Chemotherapy-Induced Nausea and Vomiting: A Systematic Literature Review. (abst – 2009) and_Synthetic_Delta_9_Tetrahydrocannabinol_as_Treatment_for_Chemotherapy_Induced_Nausea_and_V omiting:_A_Systematic_Literature_Review_


Medical Marijuana and Chemotherapy            (news – 2009)


Medical Marijuana and Radiation Therapy            (news – 2009)


Cannabinoid-2 receptor limits inflammation, oxidative/nitrosative stress, and cell death in nephropathy.  (full – 2010)


Mechanisms of Broad-Spectemetic Efficacy of Cannabinoids against Chemotherapy- Induced Acute and Delayed Vomiting                                                             (link to PDF– 2010)  8247/3/9/2930


Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting                                                                  (full – 2010) y_of_an_oromucosal_standardized_cannabis_extract_in_chemotherapy_induced_nausea_and_vomiting_










Regulation of nausea and vomiting by cannabinoids             (abst – 2010)  5381.2010.01176.x/abstract;jsessionid=56CED9CE51B025C161AA2E821BEC94ED.d01t01


Cannabidiol Attenuates Cisplatin-Induced Nephrotoxicity by Decreasing Oxidative/Nitrosative Stress, Inflammation, and Cell Death

(full – 2011)     


Brief Report: Cannabidiol Prevents the Development of Cold and Mechanical Allodynia in Paclitaxel-Treated Female C57Bl6 Mice.                                               (full – 2011)


Mechanisms of Broad-Spectrum Antiemetic Efficacy of Cannabinoids against Chemotherapy-Induced Acute and Delayed Vomiting                                                                      (link to PDF – 2010)


Marijuana Extract Might Help Prevent Chemotherapy-Related Nerve Pain  (news – 2011)


Cannabinoid ‘Completely’ Prevents Chemotherapy-Induced Neuropathy, Study Says (news – 2011)                          


Ingredient in cannabis restores taste for cancer patients               (news – 2011)


Cannabidiol may help prevent paclitaxel-induced peripheral neuropathy             (news – 2011)  peripheral-neuropathy.aspx


Marijuana component could ease pain from chemotherapy drugs                (news – 2011)


Father: Medical marijuana eased pain of my cancer-battling son               (anecdotal – 2011)


Cannabinoid type-1 receptor reduces pain and neurotoxicity produced by chemotherapy. (full – 2012)                              


The maintenance of cisplatin- and paclitaxel-induced mechanical and cold allodynia is suppressed by cannabinoid CB2 receptor activation and independent of CXCR4 signaling in models of chemotherapy-induced peripheral neuropathy                                                                                         (full – 2012)


Therapeutic utility of palmitoylethanolamide in the treatment of neuropathic pain associated with various pathological conditions: a case series                                                   (full – 2012)









Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting. (abst – 2012)                                   


Prevention of Paclitaxel-Induced Neuropathy Through Activation of the Central Cannabinoid Type 2 Receptor System                                                                        (abst – 2012)

http://www.anesthesia-  noid&searchid=1&FIRSTINDEX=130&sortspec=date&resourcetype=HWCIT


The maintenance of cisplatin- and paclitaxel-induced mechanical and cold allodynia is suppressed by cannabinoid CB2 receptor activation and independent of CXCR4 signaling in models of chemotherapy-induced peripheral neuropathy.                                                                                                 (abst – 2012)


Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: Effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment.    (abst – 2012)                                         


Prevention of paclitaxel-induced neuropathy through activation of the central cannabinoid type 2 receptor system.                                                                                    (abst – 2012)


Reefer tokin’ seniors in South Florida see pain go up in smoke                           (news – 2012)


Cannabis as Painkiller                         (news – 2012)


Share a link for